| Similar Articles |
|---|
 |
Chemistry World
August 23, 2012
Simon Campbell |
Protecting patients at all costs A new funding model is urgently required to deliver innovative medicines that meet the medical needs of the 21st century and contribute to economic growth.   |
Pharmaceutical Executive
September 1, 2010 |
Explaining the Drug Drought Industry needs to engage in a broader public debate on ways to rekindle the innovative engine in new drug discovery and development. |
HBS Working Knowledge
October 17, 2012 |
Why America Needs a Manufacturing Renaissance In their new book, Producing Prosperity: Why America Needs a Manufacturing Renaissance, Pisano and Shih discuss the dangers of underinvesting in the nation's manufacturing capabilities. |
Pharmaceutical Executive
April 1, 2011 |
Off-Label But On Point? Use of off-label drugs is a balancing act for physicians, and poses even more problems for pharma. The FDA is moving slowly to help. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
Bio-IT World
October 2005
Scott Lundstrom |
Semantic Web: Safety and Innovation Semantic Web technologies will create opportunities for improvements in discovery, development, and safety. Pharmas and biotechs should move aggressively to pilot the use of semantic technologies in these areas. |
The Motley Fool
November 30, 2010
Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. |
The Motley Fool
October 27, 2010
Ralph Casale |
Companion Diagnostics in Cancer Drug Development Diagnostic companies partnering with drug developers can make for an attractive investment segment. |
IndustryWeek
October 20, 2010 |
Innovation Nation? Manufacturers are more involved than other industries in innovation, but engagement is hardly widespread. |
Pharmaceutical Executive
April 1, 2011 |
How US Health Reform Is Hitting Canada Canada's Russell Williams, of Rx&D, talks about the impact of US health reform on his role as chief spokesman for the country's R&D industry. |
Pharmaceutical Executive
October 1, 2005
Fine & Meyer |
An 11-Step Program to Navigating Partnerships Commercial partnerships are an effective way to differentiate both research institutes and biotech companies. It is critical to recognize that while financial return is the primary driver of a commercial partnership, the cultural fit can sustain its success. |
The Motley Fool
July 12, 2010
Ryan McBride |
Synta Pharma CEO Trumpets New Top Cancer Drug Synta Pharmaceuticals has been climbing back from one of the Boston area's highest-profile clinical trial failures of 2009. |
BusinessWeek
December 29, 2010
Kelley & Cortez |
AstraZeneca's Risky Bet on Drug Discovery Instead of acquisitions and diversification, AstraZeneca is determined to find new pills in its own labs. |
InternetNews
July 27, 2010 |
FDA, FCC Push For Wireless Health Technology The government agencies are teaming up to use the latest and greatest wireless technology to improve care and reduce healthcare costs using electronic health records. |
HBS Working Knowledge
October 3, 2012
James Heskett |
Can We Bring Back the "Industrial Commons" for Manufacturing? A new book, Producing Prosperity, by Gary Pisano and Willy Shih, argues that a manufacturing renaissance is critical to the process-oriented innovation that has contributed to the worldwide dominance of the US economy. |
Chemistry World
September 30, 2010
Andrew Turley |
Bacteria factories for Taxol precursors Researchers have engineered bacteria to produce precursors of Taxol (paclitaxel), one of the most widely used cancer drugs. |
Pharmaceutical Executive
December 1, 2010
Zhu Shen |
China 2020: Walled In No More Pharma sets the pace for China's ambitious new innovation agenda |
The Motley Fool
April 26, 2011
Luke Timmerman |
FDA Says Vertex Drug a Wee Bit More Effective Than Advertised; Stock Climbs Good news for Vertex? |
IndustryWeek
January 31, 2012
Josh Cable |
GE Barometer: Executives Believe Innovation and Growth Go Hand-in-Hand However, uncertainty in the global economy is curbing their companies' appetites for risk and making it harder for them to find capital. |
The Motley Fool
June 30, 2010
Brian Orelli |
When Researchers Attack, Investors Lose Drug investors have to watch out for a lot of things that can change their stock's price: earnings reports, clinical trial results, competitor's results, and FDA decisions. |
Pharmaceutical Executive
January 21, 2014
Tim Powell |
Innovation: The Moneyball Test Successful innovation now has to align with key metrics of value; can an old baseball metaphor help guide the way? |
The Motley Fool
July 30, 2010
Brian Orelli |
3 Development-Stage Drugmakers Worth Watching A basket of potential drugs in just one company. |
Bio-IT World
Jul/Aug 2006
Eric K. Neumann |
Combining Drug Toxicity Knowledge Nearly half the drugs entering clinical trials will fail because of some form of serious toxicity that was missed in preclinical studies. These failures should not happen at such a late stage in the process. So what can be done? |
The Motley Fool
July 28, 2010
Jordan DiPietro |
3 Biotechs on Your Radar Screen It's not easy keeping track of all the drugs coming in and out of the development pipeline, but if you can stay up to date, you often have an advantage |
IndustryWeek
November 1, 2006
Thomas J. Duesterberg |
The Competitive Edge: Investing In The Future Manufacturers are urged to invest in the "intangibles." |
Pharmaceutical Executive
June 1, 2005
Jan Malek |
When Two Heads are Better R&D president isn't one job-it's two. By appointing COOs for R&D with broad operational mandates, biotech and pharmaceutical companies can ensure that operational issues get the attention they urgently require. |
Pharmaceutical Executive
April 1, 2011 |
Revisiting Reform Courts, Congress review policies and programs shaping drug costs and access. |
The Motley Fool
May 27, 2011
Brian Orelli |
Don't Believe the Obesity Hype Meta-analysis data isn't going to help Arena Pharmaceuticals' obesity drug. |
The Motley Fool
September 8, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
December 31, 2010
Brian Orelli |
2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions. |
Bio-IT World
June 2006
Eric K. Neumann |
Freeing Data, Keeping Structure We have hardly explored how to do a scientific mashup or what it means to take advantage of it. One thing is clear: If it is based on recombinant scientific data, a data description language such as RDF is necessary. Otherwise, the mashups will result in mush, unusable piles of unparsable data with unknown provenance! |
The Motley Fool
March 25, 2011
Brian Orelli |
Pfile Pfizer Under "Potential" Researchers reported promising finding from a clinical trial of Pfizer's new drug, CP-870,893, in pancreatic cancer patients in the most recent issue of the journal Science. |
The Motley Fool
January 25, 2011
Brian Orelli |
2 Keys to Amgen's Continued Success Prolia and Xgeva have to perform. |
Chemistry World
March 2011 |
Column: In the pipeline Drug discovery is an inherently risky business. Derek Lowe tries to balance some of the risk equations |
IndustryWeek
November 3, 2009 |
Benchmarking R&D Top innovators increased their research-and-development spending even as the economy sank, according to the Booz & Co. fifth annual analysis of global innovation spending. |
Bio-IT World
December 10, 2002
Jim Hall |
21st Century R&D Strategy: Atlantic or Pacific? The biopharmaceutical sector is divided by two strategic perspectives. |
Pharmaceutical Executive
July 1, 2013
Richie Etwaru |
Innovation Calls Across the C-suite: Lessons From Wall Street The lifeblood of the life sciences industry is continuous innovation; it is not a business that can survive by standing still. |
The Motley Fool
March 15, 2007
Chuck Saletta |
The American Century Is Over As more R&D takes place overseas, the technological advances and profits will follow. So should investors. |
Pharmaceutical Executive
September 1, 2011
Richard Barker |
Innovating Around Innovation The former Director General of ABPI, proposes a new agenda on how to restore public confidence in the value behind science. |
The Motley Fool
July 30, 2010
Brian Orelli |
A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs. |
HBS Working Knowledge
March 20, 2006
Huston & Sakkab |
P&G's New Innovation Model Procter & Gamble's assessment of its aging innovation process and the development of connect and develop. |
Food Processing
April 2005
Mark Andrus |
Power Lunch: Offset R&D costs with tax credit Recent changes in the tax rules will help to provide companies with additional funding for innovative product development, and may offer a new means for increasing the bottom line. |
Bio-IT World
Dec 2006/Jan 2007 |
Resolute in the New Year Industry leaders in areas from pharmacogenetics to cheminformatics found 2006 to be a year of important steps forward, but looked with even more anticipation to 2007: Allen D. Roses, SVP, Pharmacogenetics GlaxoSmithKline... etc. |
Pharmaceutical Executive
September 1, 2012
Roy F. Waldron |
Open Innovation in Pharma: Defining the Dialogue There is much talk today about "open innovation" in business and research forums, but what exactly does it mean? How does open innovation as a concept apply to the pharmaceutical sector? |
The Motley Fool
February 26, 2010
Brian Orelli |
Drug Company Cost Cuts: Careful What You Wish For Research and development is the lifeblood of future revenue. |
The Motley Fool
March 8, 2010
Brian Orelli |
Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting. |
IEEE Spectrum
October 2012
G. Pascal Zachary |
Obama, Romney, and the U.S. R&D Complex The candidates aren't saying much about their plans for the nation's R&D enterprise, but they need to -- and fast |
Chemistry World
September 9, 2014
Hepeng Jia |
R&D share for basic research in China dwindles Although China has dramatically increased its science and technology spending in recent years, the proportion of the research budget being spent on basic and applied research is shrinking. |
The Motley Fool
November 16, 2010
Luke Timmerman |
Dendreon Prepares to Take Some Heat Over Cancer Drug Prices Dendreon looking for off-label uses for its prostate cancer drug. |
The Motley Fool
October 8, 2010
Luke Timmerman |
Onyx Delays Cancer Drug Application As FDA Asks for More Data Shares fell about 7% in after-hours trading Thursday evening. |
